/
RSS Feed
Cora Sternberg
REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving improved progression-free survival and time to pain progression. Anna Lacey spoke to Cora Sternberg about her group’s results from an international phase III trial, which were announced in Barcelona.
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving improved progression-free survival and time to pain progression. Anna Lacey spoke to Cora Sternberg about her group’s results from an international phase III trial, which were announced in Barcelona.
Peter Ravdin
Significant Drop in US Breast Cancer Incidence Linked to Reduction in Hormone Replacement Therapy
REFERENCE: 2007 Chemotherapy Foundation Symposium
PETER RAVDIN, MD Anderson Cancer Center, Houston
A large registry-based study has provided strong evidence that a significant drop in breast cancer incidence in 2003 was due to the decreased use of hormone replacement therapy. Derek Thorne heard more about the study and its implications when he interviewed Peter Ravdin in New York.
PETER RAVDIN, MD Anderson Cancer Center, Houston
A large registry-based study has provided strong evidence that a significant drop in breast cancer incidence in 2003 was due to the decreased use of hormone replacement therapy. Derek Thorne heard more about the study and its implications when he interviewed Peter Ravdin in New York.
David Vesole
Low-Dose Dexamethasone Better For Newly Diagnosed Multiple Myeloma Treated With Lenalidomide
REFERENCE: 2007 Chemotherapy Foundation Symposium
DAVID VESOLE, St Vincent’s Comprehensive Cancer Center, New York
In newly diagnosed multiple myeloma, lenalidomide plus a lower dose of dexamethasone appears to be favorable for patients, and with a one-year survival rate of 96%, it could be the best result seen in this setting. During the New York symposium Derek Thorne put questions to David Vesole about his findings and their clinical implications.
DAVID VESOLE, St Vincent’s Comprehensive Cancer Center, New York
In newly diagnosed multiple myeloma, lenalidomide plus a lower dose of dexamethasone appears to be favorable for patients, and with a one-year survival rate of 96%, it could be the best result seen in this setting. During the New York symposium Derek Thorne put questions to David Vesole about his findings and their clinical implications.
Daniel DeAngelo
Young Adults With Acute Lymphoblastic Leukemia: Better Success With Pediatric Regimens
REFERENCE: 2007 Chemotherapy Foundation Symposium
DANIEL DEANGELO, Dana-Farber Cancer Institute, Boston
Young adults with ALL may be treated more effectively by using chemotherapy regimens traditionally reserved for children, rather than by using therapies recommended for adults. This came out of a talk in New York given by Daniel DeAngelo, and he later discussed with Peter Goodwin his views and preliminary results from an ongoing trial, including dose-intense asparagine depletion therapy.
DANIEL DEANGELO, Dana-Farber Cancer Institute, Boston
Young adults with ALL may be treated more effectively by using chemotherapy regimens traditionally reserved for children, rather than by using therapies recommended for adults. This came out of a talk in New York given by Daniel DeAngelo, and he later discussed with Peter Goodwin his views and preliminary results from an ongoing trial, including dose-intense asparagine depletion therapy.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080201Feb1stAjoia.mp3]
To subscribe to the ASCO Audio Journal of Oncology podcast please go to ASCO Audio Journal of Oncology in Advance Presentations or click here.
